GelMEDIX
Cambridge, US · Founded 2020 · Delaware corporation · 3 known investors
GelMEDIX is a Cambridge-based biotech developing injectable hydrogel-based cell and gene therapies for vision-restoring retinal treatment.
Also known as GelMEDIX, Inc.
Founders & leadership
Board
Investors · 3
Reported raises · per SEC filings
Form D private placements$10.1M disclosed across 4 rounds · 2020–2025
▶$747KraisedApr 2026 · 5 investors · BiotechnologyRule 506(b)
- Nasim AnnabiDirector
- Michael CimaDirector
- Reza DanaDirector
- Parinaz MotamedyDirector
- Max CotlerExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $747K
- Proceeds to insiders
- $40K
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedFeb 2025 · 2 investors · BiotechnologyRule 506(b)
- Max CotlerExecutive Officer
- Nasim AnnabiDirector
- Michael CimaDirector
- Reza DanaDirector
- Parinaz MotamedyDirector
- Offering amount
- $4M
- Amount sold
- $1M
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$1.9MraisedMar 2024 · 17 investors · BiotechnologyRule 506(b)
- Parinaz MotamedyDirector
- Max CotlerExecutive Officer
- Nasim AnnabiDirector
- Michael CimaDirector
- Reza DanaDirector
- Offering amount
- $3.5M
- Amount sold
- $1.9M
- Proceeds to insiders
- $183.3K
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$6.4MraisedAug 2022 · 4 investors · BiotechnologyRule 506(b)
- Michael CimaDirector
- Parinaz MotamedyDirector
- Arthur DriscollExecutive Officer, Director
- Nasim AnnabiDirector
- Reza DanaDirector
- Offering amount
- $8M
- Amount sold
- $6.4M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026GelMEDIX, Inc. is a regenerative medicine company developing therapies intended to restore vision loss by regenerating damaged retinal cells and preserving the ocular structures required for sight. The company's platform centers on a proprietary injectable hydrogel scaffold engineered to improve the delivery, efficacy and safety of cell and gene therapies, including the functional replacement and integration of therapeutic cells within the retina.
The company's lead program, GMX-101, is a retinal pigment epithelial (RPE) cell therapy aimed at restoring vision and halting disease progression in patients with late-stage Geographic Atrophy, a form of irreversible blindness affecting adults over 60. Beyond this lead asset, GelMEDIX states an intention to build a pipeline of next-generation therapies for degenerative eye diseases and to pursue partnerships applying its biomaterials technology to cell and gene therapies for other degenerative disorders. Its team combines expertise in biomaterials engineering, regenerative medicine and ophthalmology.
▸Full profile — market position, technology, go-to-market
Market position
The company operates in ophthalmic regenerative medicine, focusing on Geographic Atrophy, which it describes as a leading cause of irreversible blindness in adults over 60.
GelMEDIX positions its injectable hydrogel scaffold as a means of overcoming limitations of current cell therapy approaches, specifically the delivery, engraftment and integration of therapeutic cells, combined with in-house expertise spanning biomaterials engineering, regenerative medicine and ophthalmology.
Technology
GelMEDIX's core technology is a proprietary injectable hydrogel scaffold designed as a biomaterials platform for cell and gene therapy delivery. The scaffold is engineered to support the functional replacement and integration of transplanted therapeutic cells and to improve delivery, efficacy and safety relative to conventional cell therapy approaches. The platform is applied first to retinal pigment epithelial cell therapy for the retina.
Go-to-market
GelMEDIX is advancing its own pipeline of therapies for degenerative eye diseases led by GMX-101, while also seeking partnerships that apply its biomaterials platform to optimize third-party cell and gene therapies.
The company targets patients with degenerative eye diseases, with its lead program directed at late-stage Geographic Atrophy in adults over 60; it also cites partnerships with developers of cell and gene therapies for other degenerative disorders.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Competitors · 4
by search overlap
Companies competing with GelMEDIX for the same Google search keywords, organic and paid, via search-intersection analysis.
Legal entities · 1
corporate structureIn the news
▸Research sources · 1
primary sources listed
- GelMEDIXgelmedix.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does GelMEDIX do?
- GelMEDIX is a Cambridge-based biotech developing injectable hydrogel-based cell and gene therapies for vision-restoring retinal treatment.
- Who are GelMEDIX's investors?
- GelMEDIX's investors include Beacon Angels, Boston Harbor Angels, Safar Partners.
- How much funding has GelMEDIX raised?
- GelMEDIX has disclosed $10.1M raised across 4 rounds.
- Where is GelMEDIX headquartered?
- GelMEDIX is headquartered in Cambridge, US.